Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (24)
Benchalak Maneeton, Narong Maneeton, Surinporn Likhitsathian, Pakapan Woottiluk, Punjaree Wiriyacosol, Vudhichai Boonyanaruthee & Manit Srisurapanont. (2018) Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review. Neuropsychiatric Disease and Treatment 14, pages 1953-1961.
Read now
Read now
Zhuoyuan Zhong, Limin Wang, Xiaojun Wen, Yunyun Liu, Yafei Fan & Zhonglin Liu. (2017) A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials. Neuropsychiatric Disease and Treatment 13, pages 2781-2796.
Read now
Read now
Chunhui Zhao, Hui Ma, Lei Yang & Yong Xiao. (2017) Long-term bicycle riding ameliorates the depression of the patients undergoing hemodialysis by affecting the levels of interleukin-6 and interleukin-18. Neuropsychiatric Disease and Treatment 13, pages 91-100.
Read now
Read now
Eiji Harada, Osamu Shirakawa, Yoichi Satoi, Lauren B Marangell & Rodrigo Escobar. (2016) Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment 12, pages 89-97.
Read now
Read now
Ibrahim Eren, Arif Demirdas & Ikbal Civi Inanli. (2014) Evaluating The Antidepressant Efficacy of Aripiprazole Using a Chronic Mild Stress Model: An Experimental Study. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 24:1, pages 15-22.
Read now
Read now
J. Craig Nelson, Qianyi Zhang, Katarina Kelin, Elias Eriksson, Walter Deberdt & Michael Berk. (2013) Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants. Current Medical Research and Opinion 29:7, pages 827-833.
Read now
Read now
Eiji Kirino. (2012) Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Preference and Adherence 6, pages 853-861.
Read now
Read now
Lanny Bochsler, James S Olver & Trevor R Norman. (2011) Duloxetine in the acute and continuation treatment of major depressive disorder. Expert Review of Neurotherapeutics 11:11, pages 1525-1539.
Read now
Read now
Junling Wang, Xianchen Liu & C. Daniel Mullins. (2011) Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. Current Medical Research and Opinion 27:7, pages 1303-1313.
Read now
Read now
James Signorovitch, Karthik Ramakrishnan, Rym Ben-Hamadi, Andrew P. Yu, Eric Q. Wu, Heather Dworak & M. Haim Erder. (2011) Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Current Medical Research and Opinion 27:6, pages 1089-1096.
Read now
Read now
Bojana Perović, Marija Jovanović, Branislava Miljković & Sandra Vezmar. (2010) Getting the balance right: Established and emerging therapies for major depressive disorders. Neuropsychiatric Disease and Treatment 6, pages 343-364.
Read now
Read now
Trevor R Norman & James S Olver. (2010) Continuation treatment of major depressive disorder: is there a case for duloxetine?. Drug Design, Development and Therapy 4, pages 19-31.
Read now
Read now
Göran Nordström, Nicolas Despiegel, Florence Marteau, Natalya Danchenko & Khaled Maman. (2010) Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. Journal of Medical Economics 13:3, pages 516-526.
Read now
Read now
Clinton D Kilts, Alan G Wade, Henning F Andersen & Thomas E Schlaepfer. (2009) Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opinion on Pharmacotherapy 10:6, pages 927-936.
Read now
Read now
SS Stamouli, A Yfantis, E Lamboussis, A Liakouras, V Lagari, M Tzanakaki, D Giailoglou, M Legault & IA Parashos. (2009) Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients. Expert Opinion on Pharmacotherapy 10:6, pages 937-945.
Read now
Read now
Eric Q. Wu, Paul E. Greenberg, Elaine Yang, Andrew P. Yu, Rym Ben-Hamadi & M. Haim Erder. (2009) Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. Journal of Medical Economics 12:2, pages 124-135.
Read now
Read now
Sidney H. Kennedy, Henning F. Andersen & Michael E. Thase. (2009) Escitalopram in the treatment of major depressive disorder: A meta-analysis. Current Medical Research and Opinion 25:1, pages 161-175.
Read now
Read now
Feng Xie, Nicolas Despiegel, Natalya Danchenko & Karina Hansen. (2009) Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice 13:1, pages 59-69.
Read now
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Read now
Norbert Müller, Rebecca Schennach, Michael Riedel & Hans-Jürgen Möller. (2008) Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Review of Neurotherapeutics 8:4, pages 527-536.
Read now
Read now
Carlos Blanco, Mayumi Okuda, Hannah Rosenthal & Roberto Lewis-Fernandez. (2008) Duloxetine in the treatment of major depression and other psychiatric disorders. Expert Review of Clinical Pharmacology 1:2, pages 195-205.
Read now
Read now
Raymond W Lam & Lieven Annemans. (2007) Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Review of Pharmacoeconomics & Outcomes Research 7:6, pages 559-576.
Read now
Read now
Silvio R Bareggi, Emanuela Mundo, Bernardo Dell'Osso & A Carlo Altamura. (2007) The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 741-753.
Read now
Read now
. (2007) Abstracts from the 7th international forum on mood and anxiety disorders. International Journal of Psychiatry in Clinical Practice 11:4, pages 295-340.
Read now
Read now
Articles from other publishers (58)
Jiao-Zhao Yan, Guang-Xiang Li, Si-Rui Sun, Lin-Yu Cui, Yong-Yu Yin & Yun-Feng Li. (2023) A critical step in antidepressants onset: Excitation of glutamatergic pyramidal neurons in rodents' medial prefrontal cortex. Progress in Neuro-Psychopharmacology and Biological Psychiatry, pages 110911.
Crossref
Crossref
Juntao Yin, Xiaoyong Song, Chaoyang Wang, Xuhong Lin & Mingsan Miao. (2023) Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis. BMC Psychiatry 23:1.
Crossref
Crossref
Pratap Chokka, Ash Bender, Stefan Brennan, Ghalib Ahmed, Marc Corbière, David J. A. Dozois, Jeff Habert, John Harrison, Martin A. Katzman, Roger S. McIntyre, Yang S. Liu, Karen Nieuwenhuijsen & Carolyn S. Dewa. (2023) Practical pathway for the management of depression in the workplace: a Canadian perspective. Frontiers in Psychiatry 14.
Crossref
Crossref
Iván Sánchez-Iglesias & Celia Martín-Aguilar. (2023) Significant Differences and Experimental Designs Do Not Necessarily Imply Clinical Relevance: Effect Sizes and Causality Claims in Antidepressant Treatments. Journal of Clinical Medicine 12:9, pages 3181.
Crossref
Crossref
N Simple Santi, Sashi Bhusan Biswal, Birendra Narayan Naik, Jyoti Prakash Sahoo & Bhabagrahi Rath. (2023) An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder. Cureus.
Crossref
Crossref
Vishal Bhatia, Ashwani K. Dhingra, Bhawna Chopra & Kumar Guarve. (2023) A Review of Clinical Studies Assessing the Therapeutic Efficacy of
Escitalopram: A Step Towards Development. CNS & Neurological Disorders - Drug Targets 22:1, pages 41-50.
Crossref
Crossref
Kazuyuki Nakagome, Yuma Yokoi, Atsuo Nakagawa, Masayuki Tani, Gentaro Nishioka, Naoki Yoshimura, Toshiaki A. Furukawa, Koichiro Watanabe, Masaru Mimura, Akira Iwanami & Takayuki Abe. (2021) Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second-generation antidepressants: A randomized, parallel-group, non-inferiority trial. Journal of Affective Disorders 282, pages 1011-1020.
Crossref
Crossref
Yuma Yokoi, Atsuo Nakagawa, Naoki Yoshimura, Toshiaki A. Furukawa, Masaru Mimura, Akira Iwanami, Takayuki Abe & Kazuyuki Nakagome. (2019) Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second‐generation antidepressants: Study protocol for a randomized, parallel‐group, non‐inferiority trial. Neuropsychopharmacology Reports 39:4, pages 262-272.
Crossref
Crossref
Cristina Cañete-Massé, Maribel Peró-Cebollero, Esteve Gudayol-Ferré & Joan Guàrdia-Olmos. (2018) Longitudinal Estimation of the Clinically Significant Change in the Treatment of Major Depression Disorder. Frontiers in Psychology 9.
Crossref
Crossref
Philip Polychroniou, Helen Mayberg, W. Craighead, Jeffrey Rakofsky, Vivianne Aponte Rivera, Ebrahim Haroon & Boadie Dunlop. (2018) Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults. Behavioral Sciences 8:7, pages 64.
Crossref
Crossref
N. Biglia, V.E. Bounous, T. Susini, S. Pecchio, L.G. Sgro, V. Tuninetti & R. Torta. (2018) Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. European Journal of Cancer Care 27:1, pages e12484.
Crossref
Crossref
Vanessa C. Evans, Golnoush Alamian, Jane McLeod, Cindy Woo, Lakshmi N. Yatham & Raymond W. Lam. (2016) The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CNS Drugs 30:5, pages 405-417.
Crossref
Crossref
Eiji Kirino. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
465
476
.
Meinhard Kieser & Kathrin Stucke. (2014) Assessing additional benefit in noninferiority trials. Biometrical Journal 58:1, pages 154-169.
Crossref
Crossref
Ai Leng Khoo, Hui Jun Zhou, Monica Teng, Liang Lin, Ying Jiao Zhao, Lay Beng Soh, Yee Ming Mok, Boon Peng Lim & Kok Peng Gwee. (2015) Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants. CNS Drugs 29:8, pages 695-712.
Crossref
Crossref
Anthony Cleare, CM Pariante, AH Young, IM Anderson, D Christmas, PJ Cowen, C Dickens, IN Ferrier, J Geddes, S Gilbody, PM Haddad, C Katona, G Lewis, A Malizia, RH McAllister-Williams, P Ramchandani, J Scott, D Taylor & R Uher. (2015) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 29:5, pages 459-525.
Crossref
Crossref
Martin A. Katzman, Leena Anand, Melissa Furtado & Pratap Chokka. (2014) Food for thought: understanding the value, variety and usage of management algorithms for major depressive disorder. Psychiatry Research 220, pages S3-S14.
Crossref
Crossref
Barbara Nussbaumer, Laura C. Morgan, Ursula Reichenpfader, Amy Greenblatt, Richard A. Hansen, Megan Van Noord, Linda Lux, Bradley N. Gaynes & Gerald Gartlehner. (2014) Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis. CNS Drugs 28:8, pages 699-712.
Crossref
Crossref
Ursula Reichenpfader, Gerald Gartlehner, Laura C. Morgan, Amy Greenblatt, Barbara Nussbaumer, Richard A. Hansen, Megan Van Noord, Linda Lux & Bradley N. Gaynes. (2013) Sexual Dysfunction associated with Second-Generation Antidepressants in Patients with Major Depressive Disorder: Results from a Systematic Review with Network Meta-Analysis. Drug Safety 37:1, pages 19-31.
Crossref
Crossref
Raymond W. Lam, Sagar V. Parikh, Rajamannar Ramasubbu, Erin E. Michalak, Edwin M. Tam, Auby Axler, Lakshmi N. Yatham, Sidney H. Kennedy & Chinnapalli V. Manjunath. (2018) Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. British Journal of Psychiatry 203:5, pages 358-365.
Crossref
Crossref
Andrew J Bradley & Alan J Lenox-Smith. (2013) Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. Journal of Psychopharmacology 27:8, pages 740-758.
Crossref
Crossref
Eromona Whiskey & David Taylor. (2013) A review of the adverse effects and safety of noradrenergic antidepressants. Journal of Psychopharmacology 27:8, pages 732-739.
Crossref
Crossref
Siegfried Kasper & Stuart MontgomeryStuart Montgomery. 2013. Treatment‐resistant Depression. Treatment‐resistant Depression
91
105
.
Klaus P. Bøgesø & Connie Sánchez. 2012. Analogue‐Based Drug Discovery III. Analogue‐Based Drug Discovery III
269
294
.
Andrea Cipriani, Markus Koesters, Toshi A Furukawa, Michela Nosè, Marianna Purgato, Ichiro M Omori, Carlotta Trespidi & Corrado Barbui. (2012) Duloxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Anjana Bose, Joyce Tsai & Dayong Li. (2012) Early Non-Response in Patients with Severe Depression. Clinical Drug Investigation 32:6, pages 373-385.
Crossref
Crossref
Hossein Haji Ali Afzali, Jonathan Karnon & Jodi Gray. (2012) A Critical Review of Model-Based Economic Studies of Depression. PharmacoEconomics 30:6, pages 461-482.
Crossref
Crossref
Huailing Zhong, Nasser Haddjeri & Connie Sánchez. (2011) Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action. Psychopharmacology 219:1, pages 1-13.
Crossref
Crossref
Dan J. Stein & Ana Garcia Lopez. (2011) Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. Advances in Therapy 28:11, pages 1021-1037.
Crossref
Crossref
Raymond W. Lam, Marie-Josée Filteau & Roumen Milev. (2011) Clinical effectiveness: The importance of psychosocial functioning outcomes. Journal of Affective Disorders 132, pages S9-S13.
Crossref
Crossref
George I. Papakostas & Klaus Larsen. (2010) Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. European Archives of Psychiatry and Clinical Neuroscience 261:3, pages 147-156.
Crossref
Crossref
G. Laux. 2011. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
1575
1664
.
Karly P. Garnock-Jones & Paul L. McCormack. (2010) Escitalopram. CNS Drugs 24:9, pages 769-796.
Crossref
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref
Crossref
Raymond W. Lam, Sara Larsson Lönn & Nicolas Despiégel. (2010) Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. International Clinical Psychopharmacology 25:4, pages 199-203.
Crossref
Crossref
Gerald Gartlehner, Kylie Thaler, Richard A. Hansen & Bradley N. Gaynes. (2009) The General and Comparative Efficacy and Safety of Duloxetine in Major Depressive Disorder. Drug Safety 32:12, pages 1159-1173.
Crossref
Crossref
C. Spadone. (2009) Efficacité de l’escitalopram et sévérité de la dépression : nouvelles données. L'Encéphale 35:6, pages 577-585.
Crossref
Crossref
Huailing Zhong, Kasper B. Hansen, Noel J. Boyle, Kiho Han, Galina Muske, Xinyan Huang, Jan Egebjerg & Connie Sánchez. (2009) An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: Kinetic binding studies with the ALI/VFL–SI/TT mutant. Neuroscience Letters 462:3, pages 207-212.
Crossref
Crossref
George I. Papakostas, Per Bech & Maurizio Fava. 2009. Depressive Disorders. Depressive Disorders
47
74
.
Michael E. Thase & Aaron M. Koenig. 2009. Depression. Depression
22
53
.
Susan G. Kornstein, Dayong Li, Yongcai Mao, Sara Larsson, Henning F. Andersen & George I. Papakostas. (2014)
Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder:
Integrative Analysis of Four Double-Blind, Randomized Clinical Trials
. CNS Spectrums 14:6, pages 326-333.
Crossref
Crossref
Sylvia ZerjavGordon TseMichael J.W. Scott. (2009) Review of Duloxetine and Venlafaxine in Depression. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 142:3, pages 144-152.e6.
Crossref
Crossref
Stuart A. Montgomery & Hans-Jürgen Möller. (2009) Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. International Clinical Psychopharmacology 24:3, pages 111-118.
Crossref
Crossref
Andrea Cipriani, Claudio Santilli, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Hugh McGuire, Rachel Churchill & Corrado Barbui. (2009) Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2016:5.
Crossref
Crossref
C. Spadone. (2009) Formes sévères de dépression : efficacité de l’escitalopram. L'Encéphale 35:2, pages 152-159.
Crossref
Crossref
Paolo Girardi, Maurizio Pompili, Marco Innamorati, Michele Mancini, Gianluca Serafini, Lorenzo Mazzarini, Antonio Del Casale, Roberto Tatarelli & Ross J. Baldessarini. (2009) Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Human Psychopharmacology: Clinical and Experimental 24:3, pages 177-190.
Crossref
Crossref
A.G. Wade, T.E. Schlaepfer, H.F. Andersen & C.D. Kilts. (2009) Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of Psychiatric Research 43:5, pages 568-575.
Crossref
Crossref
Andrea Cipriani, Toshiaki A Furukawa, Georgia Salanti, John R Geddes, Julian PT Higgins, Rachel Churchill, Norio Watanabe, Atsuo Nakagawa, Ichiro M Omori, Hugh McGuire, Michele Tansella & Corrado Barbui. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 373:9665, pages 746-758.
Crossref
Crossref
Katsumasa Muneoka. (2009) Pharmacotherapy of Major Depressive Disorder: Focus on Duloxetine. Clinical Medicine. Therapeutics 1, pages CMT.S1988.
Crossref
Crossref
A. Prakash, R. C. Risser & C. H. Mallinckrodt. (2008) The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. International Journal of Clinical Practice 62:8, pages 1147-1158.
Crossref
Crossref
Raymond W. Lam, Henning F. Andersen & Alan G. Wade. (2008) Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. International Clinical Psychopharmacology 23:4, pages 181-187.
Crossref
Crossref
IM AndersonIN Ferrier, RC Baldwin, PJ Cowen, L Howard, G Lewis, K Matthews, RH McAllister-Williams, RC Peveler, J Scott & A Tylee. (2008) Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 22:4, pages 343-396.
Crossref
Crossref
Michael E. ThaseTimothey Denko. (2008) Pharmacotherapy of Mood Disorders. Annual Review of Clinical Psychology 4:1, pages 53-91.
Crossref
Crossref
&NA;. (2008) Duloxetine: a guide to its use in major depressive disorder. Drugs & Therapy Perspectives 24:3, pages 5-8.
Crossref
Crossref
P. Van Dijck. (2007) Escitalopram, un développement clinique complet. L'Encéphale 33, pages 134-139.
Crossref
Crossref
Silvio R Bareggi, Emanuela Mundo, Bernardo Dell'Osso & A Carlo Altamura. (2007) The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 741-753.
Crossref
Crossref
James E Frampton & Greg L Plosker. (2007) Duloxetine. CNS Drugs 21:7, pages 581-609.
Crossref
Crossref
Jonathan Rabinowitz, Janet Williams, Nanco Hefting, Ariana Anderson, Brianne Brown, Dong-Jing Fu, Bashkim Kadriu, Alan Kott, Atul Mahableshwarkar, Jan Sedway, David Williamson, Christian Yavorsky & Nina R. Schooler. (2022) Consistency Checks to Improve Measurement with the Hamilton Rating Scale for Anxiety (HAM-A). SSRN Electronic Journal.
Crossref
Crossref